The role of inflammation in the pathophysiology of acute coronary syndromes;Die rolle der inflammation in der pathophysiologie akuter koronarsyndrome

Wiener Klinische Wochenschrift

Volumn 117, Issue 13-14, 2005, Pages 445-455

  Alber, Hannes F ^a   Suessenbacher, Alois ^a   Weidinger, Franz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Acute coronary syndrome; Atherosclerosis; CRP; Inflammation; Soluble CD40 ligand

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CYTOKINE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; STATIN;

ATHEROSCLEROTIC PLAQUE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MACROPHAGE; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE; THROMBOCYTE ACTIVATION;

ACUTE DISEASE; ANGINA, UNSTABLE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD40; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; CYTOKINES; HUMANS; MYOCARDIAL INFARCTION; SYNDROME; VASCULITIS;

EID: 23844452421     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0399-7     Document Type: Review

References (117)

1. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442
2. Reddy KS (2004) Cardiovascular disease in non-Western countries. N Engl J Med 350: 2438-2440
3. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126
4. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143
5. Miller DD, Craig FE, Dressler FA, Aguirre FV, Farrar MA, Breland CM, Donohue TJ, Kern MJ, Bach RG (1995) Immunohistochemical characterization of immune cell composition and cytokine receptor expression in human coronary atherectomy tissue. Coron Artery Dis 6: 965-972
6. Nadrchal R, Makristathis A, Apfalter P, Rotter M, Trubel W, Huk I, Polterauer P, Hirschl AM (1999) Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction. Wien Klin Wochenschr 111: 153-156
7. el-Rabadi K, Gottsauner-Wolf M, Christ G, Maurer G, Huber K (2001) Chlamydia antibody titers in patients with coronary disease: relations to age and clinical stage. Wien Klin Wochenschr 113: 727-730
8. Ieven MM, Hoymans VY (2005) Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol 43: 19-24
9. Wick G, Xu Q (1999) Atherosclerosis - an autoimmune disease. Exp Gerontol 34: 559-566
10. Metzler B, Xu Q, Wick G (1998) The role of (auto-) immunity in atherogenesis. Wien Klin Wochenschr 110: 350-355
11. Benagiano M, Azzurri A, Ciervo A, Amedei A, Tamburini C, Ferrari M, Telford JL, Baldari CT, Romagnani S, Cassone A, D'Elios MM, Del Prete G (2003) T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 100: 6658-6663
12. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874
13. Moons AH, Levi M, Peters RJ (2002) Tissue factor and coronary artery disease. Cardiovasc Res 53: 313-325
14. Mallat Z, Tedgui A (2001) Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 88: 998-1003
15. Granger DN, Vowinkel T, Petnehazy T (2004) Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931
16. Levi M, van der Poll T, Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704
17. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347: 185-192
18. Knapp S, Branger J, van der Poll T (2002) Advances in research of the inflammatory response: the importance of toll-like receptors. Wien Med Wochenschr 152: 552-554
19. Prager GW, Binder BR (2004) Genetic determinants: is there an "atherosclerosis gene"? Acta Med Austriaca 31: 1-7
20. Manolio TA, Boerwinkle E, O'Donnell CJ, Wilson AF (2004) Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol 24: 1567-1577
21. Yokoya K, Takatsu H, Suzuki T, Hosokawa H, Ojio S, Matsubara T, Tanaka T, Watanabe S, Morita N, Nishigaki K, Takemura G, Noda T, Minatoguchi S, Fujiwara H (1999) Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation 100: 903-909
22. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V (1985) Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 5: 609-616
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326: 242-250
24. de Boer OJ, van der Wal AC, Teeling P, Becker AE (1999) Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 41: 443-449
25. Schroeder AP, Falk E (1995) Vulnerable and dangerous coronary plaques. Atherosclerosis 118 [Suppl]: S141-149
26. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, Weyand CM (1999) Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 100: 2135-2139
27. Madjid M, Awan I, Willerson JT, Casscells SW (2004) Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 44: 1945-1956
28. Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L (2005) Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 95: 452-456
29. Morrow DA, Braunwald E (2003) Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108: 250-252
30. Lind L (2003) Circulating markers of inflammation and atherosclerosis. Atherosclerosis 169: 203-214
31. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397
32. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98: 1487-1494
33. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818
34. Prasad KS, Andre P, Yan Y, Phillips DR (2003) The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 10: 356-361
35. Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, Ochs HD (1998) Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood 92: 2421-2434
36. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94: 1931-1936
37. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594
38. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P (1999) Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189: 843-853
39. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106: 981-986
40. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P (2000) CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 156: 7-14
41. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394: 200-203
42. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL (2004) Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 93: 6-9
43. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Guilestad L (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100: 614-620
44. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108: 1049-1052
45. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104-1111
46. (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429-1435
47. Berglund U, Wallentin L (1991) Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 12: 428-433
48. Nyman I, Larsson H, Wallentin L (1992) Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 340: 497-501
49. Paul A, Calleja L, Camps J, Osada J, Vilella E, Ferre N, Mayayo E, Joven J (2000) The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68: 457-465
50. Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109: II18-26
51. Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107
52. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebruany VL, Gurbel PA, Gaulden LH, Felker GM, Whellan DJ, O'Connor CM (2004) Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 93: 783-785
53. DeGraba TJ (2004) Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke 35: 2712-2719
54. Graninger M, Reiter R, Drucker C, Minar E, Jilma B (2004) Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 44: 335-339
55. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX (2005) Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178: 9-17
56. Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719
57. Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109: 1142-48
58. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM, Jr. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965
59. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307
60. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718
61. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560-1566
62. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071-1080
63. Ridker PM (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108: 2292-2297
64. Chew DP, Bhatt DL (2001) Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 3: 63-71
65. Hermann A, Rauch BH, Braun M, Schror K, Weber AA (2001) Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12: 74-82
66. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Froland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF (2003) Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41: 275-279
67. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G (2002) Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106: 399-402
68. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843
69. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD (1999) von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19: 3071-3078
70. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242
71. Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537-547
72. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512
73. Strandberg TE, Tilvis RS (2000) C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 20: 1057-1060
74. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979
75. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731-733
76. Keshavamurthy CB, Kane GR, Magdum AP, Sahoo PK (2000) Serum fibrinogen and C-reactive protein levels predict major adverse cardiac events in unstable angina. Indian Heart J 52: 36-39
77. Heeschen C, Hamm CW, Bruemmer J, Simoons ML (2000) Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 Anti-Platelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 35: 1535-1542
78. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Yui Y, Fukuda N (1999) Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions. Jpn Circ J 63: 976-980
79. Lee WH, Lee Y, Kim JR, Chu JA, Lee SY, Jung JO, Kim JS, Kim S, Seo JD, Rhee SS, Park JE (1999) Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients. Exp Mol Med 31: 159-164
80. de Winter RJ, Bholasingh R, Lijmer JG, Koster RW, Gorgels JP, Schouten Y, Hoek FJ, Sanders GT (1999) Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 42: 240-245
81. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99: 855-860
82. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, Grillo RL, Cianflone D, Biasucci LM, Maseri A (1998) Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 82: 715-719
83. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844
84. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S (1997) C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96: 778-784
85. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462-466
86. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI (1996) Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17: 1345-1349
87. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332: 635-641
88. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424
89. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, Bazzino OO (1999) Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 100: 1958-1963
90. Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, Corea L (1999) C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 83: 1595-1599
91. Nikfardjam M, Mullner M, Schreiber W, Oschatz E, Exner M, Domanovits H, Laggner AN, Huber K (2000) The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 247: 341-345
92. Gheno G, Libardoni M, Zeppellini R, Cucchini F (1999) C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction. Cardiologia 44: 1023-1028
93. Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96: 4204-4210
94. Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Boccara A, Aubry P, Nicaise P, Brochet E, Juliard JM, Himbert D, Assayag P (1998) Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol 82: 845-850
95. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 98: 294-299
96. Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano A (1997) C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol 80: 1002-1006
97. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A (1998) Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98: 2370-2376
98. Berk BC, Weintraub WS, Alexander RW (1990) Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 65: 168-172
99. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94: 874-877
100. Caligiuri G, Liuzzo G, Biasucci LM, Maseri A (1998) Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol 32: 1295-1304
101. Holvoet P, Collen D, Van de Werf F (1999) Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 281: 1718-1721
102. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101: 2149-2153
103. Liuzzo G, Vallejo AN, Kopecky SL, Frye RL, Holmes DR, Goronzy JJ, Weyand CM (2001) Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 103: 1509-1514
104. Rallidis LS, Gika HI, Zolindaki MG, Xydas TA, Paravolidakis KE, Velissaridou AH (2003) Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 92: 1195-1197
105. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA (2001) Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J 22: 1226-1234
106. Suefuji H, Ogawa H, Yasue H, Sakamoto T, Miyao Y, Kaikita K, Soejima H, Misumi K, Miyamoto S, Kataoka K (2000) Increased plasma level of soluble E-selectin in acute myocardial infarction. Am Heart J 140: 243-248
107. Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD (2001) Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 85: 989-994
108. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Aldama G, Pizzi C, Quiles J, Kaski JC (2004) Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 90: 847-852
109. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W (1997) Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 30: 703-707
110. Neri Serneri GG, Frisco D, Martini F, Gori AM, Brunelli T, Poggesi L, Rostagno C, Gensini GF, Abbate R (1997) Acute T-cell activation is detectable in unstable angina. Circulation 95: 1806-1812
111. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, Wallin R (1989) Neutrophil function in ischemic heart disease. Circulation 79: 549-556
112. Dinerman JL, Mehta JL, Saldeen TG, Emerson S, Wallin R, Davda R, Davidson A (1990) Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 15: 1559-1563
113. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, Tommasi M, Rebuzzi AG, Maseri A (1996) Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 27: 611-616
114. Lee KW, Lip GY, Blann AD (2004) Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110: 2355-2360
115. Kranz A, Rau C, Kochs M, Waltenberger J (2000) Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 32: 65-72
116. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, Zeiher AM (2004) Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291: 435-141
117. Tamura K, Nakajima H, Rakue H, Sasame A, Naito Y, Nagai Y, Ibukiyama C (1999) Elevated circulating levels of basic fibroblast growth factor and vascular endothelial growth factor in patients with acute myocardial infarction. Jpn Circ J 63: 357-361